These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 27564404)

  • 41. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
    Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
    Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.
    Zhang J; Cao D; Yu S; Chen L; Wei D; Shen C; Zhuang L; Wang Q; Xu X; Tong Y
    BMC Cancer; 2018 Apr; 18(1):467. PubMed ID: 29695237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages.
    Cheng L; Liu J; Liu Q; Liu Y; Fan L; Wang F; Yu H; Li Y; Bu L; Li X; Wei W; Wang H; Sun G
    Int J Biol Sci; 2017; 13(6):723-734. PubMed ID: 28655998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis.
    Pradhan R; Paul S; Acharya SS; Sinha S; Dash SR; Kundu CN
    J Nutr Biochem; 2024 Mar; 125():109568. PubMed ID: 38185347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-L2
    Tavukcuoglu E; Horzum U; Yilmaz KB; Esendagli G
    Immunol Cell Biol; 2020 Feb; 98(2):152-164. PubMed ID: 31845380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
    Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
    PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
    Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
    Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-L1 Expression in Mastocytosis.
    Williams M; Lidke DS; Hartmann K; George TI
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
    Jalali S; Price-Troska T; Paludo J; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Ansell SM
    Blood Adv; 2018 Aug; 2(15):1985-1997. PubMed ID: 30104397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 59. Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
    Tanaka R; Ichimura Y; Kubota N; Saito A; Nakamura Y; Ishitsuka Y; Watanabe R; Fujisawa Y; Mizuno S; Takahashi S; Fujimoto M; Okiyama N
    J Invest Dermatol; 2022 Jan; 142(1):145-154.e8. PubMed ID: 34310947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.